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the £20,000 and £30,000 willingness-to-pay thresholds for both treatment-naïve
patients and treatment-experienced patients regardless of IL-28B subtypes.
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OBJECTIVES: Develop an economic evaluation of regimes Tenofovir/Emtricitabina
(Truvada
®
)EFV versus TDFFTCLPV/r, ABC3TCEFV, ABC3TCLPV/r,
ZDV3TCEFV in naïve patients infected with HIV through a cost-effectiveness
study from the public health system Mexican perspective. METHODS: We devel-
oped an economic Markov model to compare information on the effectiveness,
utility and costs of the use of Tenofovir/Emtricitabina (Truvada
®
)EFV versus
TDFFTCLPV/r, ABC3TCEFV, ABC3TCLPV/r, ZDV3TCEFV over a 2 year
period with six-month cicles. Efficacy was measured by the percentage of individ-
uals with plasmaHIV RNA 50 copies/mL and Qalys, based on a systematic review
and meta-analysis of clinical trial of regimens in treatment-naïve populations.
Model follows the recommendations of antiretroviral persons handling Guide with
HIV in Mexico (2010 SSA). The direct costs, treatment of adverse events, cost of
failure of the treatment and costs of medical attention of HIV were estimated and
were obtained from the mexican public health institutions. All costs were calcu-
lated in 2011 mexican pesos (MXP). Incremental cost effectiveness ratios were
expressed as cost per 1% of individuals with plama HIV RNA50 copies/ML and
Qalys. Costs and outcomes were discounted at 5%. Probabilistic sensitivity analy-
ses viaMonte Carlo simulations and a budget impact analysis (BIA) were perfomed.
RESULTS:Tenofovir/Emtricitabina (Truvada
®
)EFVwasmost effective than others
comparators with a probability of 0.562 HIV RNA 50 copies/mL and 1.614 Qalys.
Tenofovir/Emtricitabina (Truvada
®
)EFV resulted as the alternative with less av-
erage total cost per patients ($91,439.77). Tenofovir/Emtricitabina (Truvada®)EFV
is a dominant option and cost saving compared to the alternatives. Deterministic
probabilistic sensitivity analysis showed that the findings are robust. The analysis
of BIA show that public health system mexican could save about $140,480,959 if
they use Tenofovir/Emtricitabina (Truvada®)EFV rather than other options in
these patients. CONCLUSIONS: Tenofovir/Emtricitabina (Truvada®)EFV is an ef-
ficient and cost-saving drug on 96 weeks for the treatment of adult naïve patients
with HIV infection in Mexico.
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FROM RANDOMIZED CONTROLLED TRIALS TO REAL WORLD: THE COALA
STUDY
Foglia E1, Restelli U1, Bonizzoni E2, Bonfanti P3, Rizzardini G4, Ricci E4, Porazzi E1,
Scolari F1, Vanzago A1, Croce D1
1University Carlo Cattaneo - LIUC, Castellanza, Varese, Italy, 2University of Milan, Faculty of
Medicine and Surgery, Milano, Milano, Italy, 3A. Manzoni Hospital, Lecco, Lecco, Lecco, Italy,
4“L. Sacco” Hospital Authority, Milano, Milano, Italy
OBJECTIVES:What happens when technologies leave Randomized Controlled Tri-
als and approach the real world? Sometimes no answers are provided to this ques-
tion. The aim of the COALA study was to evaluate, taking the Italian NHS (payer)
perspective, the lifetime cost-utility of lopinavir/ritonavir vs. atazanavir  ritona-
vir, with a tenofovir-emtricitabine backbone, in a sample of 319 naïve patients
starting from, and developing, the assumptions of the Broder (2011) Markovmicro-
simulationmodel.METHODS: The health andmonetary outcomes associated with
ATVr and LPV/r regimens, were analyzed considering: 8 health states, incidence
of diarrhea and/or hyperbilirubinemia, AIDS events, opportunistic infections, and
CHD events and, for the first time in an economic evaluation concerning HIV
patients, CKD. Patients were enrolled in one of two scenarios: LPV/r or ATVr
(ATV1), and followed first or second line treatment. The two lines were both mod-
elled at an individual patient level. A sensitivity analysis regarding ATVr arm
(ATV2) was assessed, in order to replicate the results of the CASTLE trial study, and
to compare them with an ATV1 arm. The total cost per patient was calculated
considering drugs costs, clinical effectiveness data, as well as institutional guide-
lines, protocols and the Lombardy Region reimbursement tariffs. RESULTS: LPV
was assessedwith a gain in terms ofQALY equal to 0.150 to 0.447. Themodel results
show a higher incidence of cardiovascular events (6.5 per 1,000 inhabitants) for the
LPV arm, and a lower incidence of CKD (27.1 vs. 110.9-135.3) for LPV.
CONCLUSIONS: Considering the economic performance, there was an annual eco-
nomic per capita advantage between €73 and €138. This, in terms of QALY and
reduction of costs, reveals that LPV/r treatment gives a higher economical perfor-
mance and is more cost-effective compared with ATVr.
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OBJECTIVES: Poor adherence to HIV antiretroviral therapies (ART) increases the
risk of incomplete viral suppression, development of viral resistance, progression
to acquired immune deficiency syndrome, and death. However, there is little un-
derstanding of the impact of specific treatment-related adverse events (AEs) on
adherence. This meta-analysis was conducted to assess the effects of treatment-
related AEs on adherence to ART in adult HIV-infected patients. METHODS: A
systematic review of studies involving HIV-infected patients aged 16 years and
reporting an odds ratio (OR) for factors affecting adherence to ART was conducted.
Embase and MEDLINE databases were searched between 1996 and 2010. Bibliogra-
phies of identified review papers were also searched. Studies conducted in popu-
lations limited to a particular demographic characteristic or behavioral risk factor
were excluded. To qualify for inclusion into the meta-analysis, treatment-related
AEs had to be defined similarly across studies. Multiple ORs from the same study
were included where study sub-groups were distinct. Random effects models were
used to pool ORs. RESULTS: Nineteen studies and 18 ART-related AEs were in-
cluded in the analysis. Adherence to ART was significantly lower in patients with
non-specific AEs than in patientswho did not experience anyAEs (OR0.62; 95%CI:
0.46-0.83). Patients with specific AEs such as cough (OR0.65; 0.53-0.79), fatigue
(OR0.63; 0.43-0.92), confusion (OR0.35; 0.18-0.66), anxiety (OR0.63; 0.41-0.95),
taste disturbances (OR0.49; 0.30-0.77), nausea (OR0.57; 0.43-0.77), and loss of
appetite (OR0.54; 0.32-0.93) were significantly less likely to adhere to ART com-
pared to patients without these AEs. Diarrhea, insomnia, sexual dysfunction, lip-
odystrophy, numbness, pain when swallowing, tingling in mouth/tongue, derma-
tological conditions, abdominal pain, and vomiting were not significantly
associated with adherence, although trends toward decreased adherence were
observed. CONCLUSIONS: Specific treatment-related AEs can significantly de-
crease adherence to ART. Knowledge of these effects may allow for targeted man-
agement of AEs to improve ART adherence and clinical outcomes.
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OBJECTIVES: The standard of care for hepatitis C (ribavirin and peginterferon) has
been found to be associated with an increased risk of anemia. The objective of this
study was to investigate the effect anemia has on health status and work produc-
tivity among patients currently treated for hepatitis C. METHODS: Data from the
2011 U.S. National Health and Wellness Surveys were used. Among respondents
who were currently or had formerly been treated for hepatitis C, those with and
without a diagnosis of anemia were compared on health status (using the SF-12v2)
andwork productivity (using theWPAI questionnaire) using general linearmodels.
Demographics, health behaviors, and comorbidities were also measured and in-
cluded as covariates. RESULTS: A total of 305 patients were currently or formerly
treated for hepatitis C. Of these patients, 22 reported having been diagnosed with
anemia (7.21%). The presence of anemia was associated with significantly lower
mental component summary scores (Mean37.00 vs. Mean45.21) and worse
health utilities (Mean0.53 vs. Mean0.67) (all ps.05). Impairment in daily activ-
ities was significantly higher among those with anemia (Mean65.00% vs.
Mean39.33%, p.05). Fewpatientswere currently employed (n7with anemia vs.
n121 without anemia), however, absenteeism (Mean34.00% vs. Mean5.79%),
presenteeism (Mean51.43% vs. Mean23.67%), and overall work impairment
(Mean61.00% vs. 25.98%) were all significantly higher among those with anemia
(all ps.05). The health status and activity impairment differences remained after
controlling for age, gender, ethnicity, smoking and theCharlson comorbidity index.
CONCLUSIONS: These results suggest that presence of anemia is associated with a
substantial humanistic and indirect cost burden among patients who are treated
for hepatitis C. Novel treatments which reduce the rate of anemia may result in a
substantial improvement in patient outcomes.
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OBJECTIVES: Although prior studies have examined the burden of hepatitis C
(HCV) within individual countries, no study has compared the burden across coun-
tries using a consistent methodology. The aim of this study was to quantify the
burden of HCV in the United States (US), France, Germany, Italy, Spain, the UK,
China, and Japan.METHODS: The 2010 5EU (N57,805), 2009 US (N75,000), 2008/
2009 Japan (N37,683), and 2009/2010 urban China (N33,261) waves of the Na-
tional Health andWellness Survey were used as data source. Within each country,
patients with a self-reported diagnosis of HCV were compared with those who did
not report a diagnosis of HCV on sociodemographics, health behaviors, comorbidi-
ties, and health outcomes (health status using the SF-12v2,work productivity using
the WPAI, and healthcare resource use in the past six months). The effect of HCV
was examined using regression analysis applying samplingweights. RESULTS:The
prevalence of HCV ranged from 0.26% (China) to 1.42% (Italy). Patients in Japan and
Italy (61.60 and 61.02 years, respectively) were the oldest, while patients in the US
were the most likely to be obese (39.31%) and have concomitant anxiety (38.43%)
and depression (46.05%) compared with other countries. Pooling countries and
adjusting for sociodemographics, health behaviors, and comorbidities, HCV was
associated with significantly lower physical component summary scores (b-2.51)
and health utilities (b-0.04) and greater overall work impairment (b8.79), physi-
cian visits (b2.91), and emergency department visits (b0.30) (all ps.05). The
effects on health status were strongest in the US and UK while the effects on
healthcare resource use were strongest in Japan. CONCLUSIONS: HCV was associ-
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